Targeting ZNF410 in erythroid cells led to CHD4 downregulation and HbF induction, without compromising erythroid cell differentiation, thus validating ZNF410 as a promising potential target for treating hemoglobinopathies. The gene discussed is ZNF410; the disease is hemoglobinopathy.